235 results
6-K
EX-99
BLRX
Bioline Rx Ltd
6 May 24
Current report (foreign)
7:14am
with Leukemia: For the purpose of hematopoietic stem cell (HSC) mobilization, APHEXDA may cause mobilization of leukemic cells and subsequent contamination
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
medication and local treatments post-dose, as needed.
Tumor Cell Mobilization in Patients with Leukemia: For the purpose of hematopoietic stem cell (HSC
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to exercise this Warrant pursuant … of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors … established for such purpose for services rendered to the Company; provided that any securities so issued to consultants shall only be issued
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
or distribution of this prospectus supplement in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside … with the SEC on March 26, 2024, and any amendment or report filed for the purpose of further updating that description.
We also incorporate by reference
20-F/A
EX-2.1
lpybb szsrmp61o3t3j
26 Mar 24
Annual report (foreign) (amended)
4:57pm
20-F/A
law6j3hu0g4
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-1
4yj42tzvpy6 eflg8p3a
16 Feb 24
Current report (foreign)
7:07am
S-8
k0iz1yo4f03khfrsi
29 Dec 23
Registration of securities for employees
4:20pm
F-3
EX-5.2
h7rkr
29 Dec 23
Shelf registration (foreign)
4:15pm
F-3
jdu4dbo5
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
5iql3kbvomq4
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
ls4z1j1hda1
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
h7is7kkeqgmvt7s20n
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
sbk136go1x 0rnwwza
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
8rh7q08pljld02u
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
p33he0pbp1oxndeg2tc
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm